Eli Lilly's rare sales miss for weight-loss drug sends shares tumbling
Lilly's shares fall 8% as drug sales miss expectations
CEO David Ricks cited physical and financial constraints at wholesalers for the shortfall
Lilly slashes annual profit forecast due to acquisition charges and higher costs
Adds Lilly CEO comments from investor call in paragraphs 5-7
By Bhanvi Satija and Patrick Wingrove
Oct 30 (Reuters) -Eli Lilly's LLY.N high profile weight-loss and diabetes drugs fell short of Wall Street sales estimates on Wednesday as supplies sat in warehouses, a 180-degree turn for the company after long struggling to meet outsized demand.
Lilly shares were off 8%, wiping out nearly $70 billion from the Indianapolis-based drugmaker's market value.
Both its weight-loss drug Zepbound and diabetes treatment Mounjaro have been contending with high demand that has led to shortages, but last quarter Lilly said it had ramped up manufacturing and was able to fill back orders at wholesalers. Now Lilly's drugs are no longer in shortage and distributors are working through the supplies, it said.
Drug wholesalers, or distributors, purchase medicines like Zepbound from manufacturers and sell them to hospitals, clinics, pharmacies and other healthcare providers.
Lilly CEO David Ricks said during an investor call that a factor in the sales miss was customers of wholesalers and resellers choosing how many doses to stock based on their own physical and financial constraints. The drugs must be refrigerated during transport and storage.
Ricks told CNBC there was excess supply of the drugs but that the company had not yet started advertising Zepbound and had held back on international launches to focus on increasing U.S. inventory.
"We haven't been stimulating demand the way we had originally planned," Ricks said.
Sales of Mounjaro were $3.11 billion, while Zepbound brought in $1.26 billion. Analysts were looking for Mounjaro sales of $4.20 billion and $1.69 billion for Zepbound for the quarter, according to LSEG data. They expect the drugs to make a combined $19 billion this year.
The miss comes despite prescriptions of Zepbound and Mounjaro continuing to increase in the U.S. Lilly filled an average of around 140,000 Zepbound prescriptions per week this quarter, compared to just over 93,000 per week last quarter, according to IQVIA data shared by an analyst.
J.P. Morgan analyst Chris Schott said the results suggested wholesalers had utilized their existing inventories without placing additional new orders as analysts had expected.
Lilly's shares had been up 55% so far this year, making it the world's most valuable healthcare company, as investors bet on the success of the weight-loss drug.
Mounjaro and Zepbound compete with Novo Nordisk's NOVOb.CO popular Ozempic and Wegovy. Novo, whose U.S. listed shares were down almost 1%, has been aggressively marketing Wegovy on U.S. television.
Lilly also slashed its annual adjusted profit forecast to $13.02 to $13.52 per share, compared to prior view of $16.10 to $16.60, citing acquisition charges in the third quarter.
The previously disclosed $2.8 billion acquisition-related charge and higher manufacturing costs also contributed to the third-quarter profit miss.
'A BLIP IN THE ROAD'
Zepbound and Mounjaro were in short supply for much of this year due to soaring demand for the medicines that have been shown to help patients lose an average of 20% of their weight. Lilly said supply had started to catch up with demand last quarter.
David Heupel, senior portfolio manager at Thrivent Financial for Lutherans, which owns about 370,000 Lilly shares, called third-quarter results "a blip in the road" and said he was not concerned about overall demand for Lilly's weight-loss and diabetes drugs.
It's just "a consequence of a market that's still in its infancy," Heupel said.
Lilly has invested billions of dollars to expand production of Mounjaro and Zepbound, both known chemically as tirzepatide, including about $7 billion in its Indiana site and facilities in Ireland. The drug is sold under the brand name Mounjaro for both diabetes and weight loss outside the U.S.
Lilly trimmed the upper end of its full-year sales forecast by $600 million to $46 billion. It maintained the lower end at $45.4 billion.
Lilly and Novo Nordisk have been racing to increase capacity and meet unprecedented demand for a weight-loss market some analysts estimate could reach $150 billion in annual revenue by the next decade.
In August, Novo trimmed its full-year profit forecast and reported a rare miss on quarterly sales of Wegovy.
Zepbound and Mounjaro prescriptions https://reut.rs/3YILy49
Sales of Lilly's popular weight-loss and diabetes drugs https://reut.rs/4e2EEuY
Reporting by Bhanvi Satija and Christy Santhosh in Bengaluru and Patrick Wingrove in New York; Editing by Sriraj Kalluvila and Bill Berkrot
Ultime news
Disclaimer: le entità di XM Group forniscono servizi di sola esecuzione e accesso al nostro servizio di trading online, che permette all'individuo di visualizzare e/o utilizzare i contenuti disponibili sul sito o attraverso di esso; non ha il proposito di modificare o espandere le proprie funzioni, né le modifica o espande. L'accesso e l'utilizzo sono sempre soggetti a: (i) Termini e condizioni; (ii) Avvertenza sui rischi e (iii) Disclaimer completo. Tali contenuti sono perciò forniti a scopo puramente informativo. Nello specifico, ti preghiamo di considerare che i contenuti del nostro servizio di trading online non rappresentano un sollecito né un'offerta ad operare sui mercati finanziari. Il trading su qualsiasi mercato finanziario comporta un notevole livello di rischio per il tuo capitale.
Tutto il materiale pubblicato sul nostro servizio di trading online è unicamente a scopo educativo e informativo, e non contiene (e non dovrebbe essere considerato come contenente) consigli e raccomandazioni di carattere finanziario, di trading o fiscale, né informazioni riguardanti i nostri prezzi di trading, offerte o solleciti riguardanti transazioni che possano coinvolgere strumenti finanziari, oppure promozioni finanziarie da te non richieste.
Tutti i contenuti di terze parti, oltre ai contenuti offerti da XM, siano essi opinioni, news, ricerca, analisi, prezzi, altre informazioni o link a siti di terzi presenti su questo sito, sono forniti "così com'è", e vanno considerati come commenti generali sui mercati; per questo motivo, non possono essere visti come consigli di investimento. Dato che tutti i contenuti sono intesi come ricerche di investimento, devi considerare e accettare che non sono stati preparati né creati seguendo i requisiti normativi pensati per promuovere l'indipendenza delle ricerche di investimento; per questo motivo, questi contenuti devono essere considerati come comunicazioni di marketing in base alle leggi e normative vigenti. Assicurati di avere letto e compreso pienamente la nostra Notifica sulla ricerca di investimento non indipendente e la nostra Informativa sul rischio riguardante le informazioni sopra citate; tali documenti sono consultabili qui.
